Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are both biotechs which rose to prominence as a result of their efforts to develop and commercialize a coronavirus vaccine. Only Novavax has largely accomplished that goal so far, though its product isn't yet approved for sale in the U.S. But do its recent successes make it a better buy? The argument for buying Novavax is that in the near term it'll be raking in global sales of its coronavirus vaccine, which will continue to get approved for use in more and more jurisdictions.
It's more important than ever to make highly selective investment decisions with a struggling stock market, challenging economic issues, and dangerous geopolitical tensions. Inovio Pharmaceuticals encountered a series of headwinds in its quest to market its experimental coronavirus vaccine, INO-4800. Recently, the company discontinued a phase 3 clinical study for this candidate.
No matter your level of experience investing money on Wall Street, it's been a rough year. Meanwhile, the technology-driven Nasdaq Composite declined close to 30% from its November all-time high, firmly placing it in a bear market. This is why Wall Street analysts typically have a bullish outlook on many of the companies they cover.